Literatur

NVL Chronische KHK, 5. Auflage, 2019. Version 1

Druckversion (PDF ) | Empfehlungsübersicht weitere Informationen 

1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 4. Auflage. Version 1. 2016 [cited: 2017-06-26]. DOI: 10.6101/AZQ/000267. http://doi.org/10.6101/AZQ/000267.

2. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden. Version 5.0. Köln: IQWiG; 2017. http://www.iqwig.de/download/Allgemeine-Methoden_Version-5-0.pdf.

3. Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: Toward International Standards for Clinical Practice Guidelines. Ann Intern Med 2012; 156(7):525–31. http://www.ncbi.nlm.nih.gov/pubmed/22473437.

4. Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. Qualitatssich. 2002; 96(Suppl III):3–60.

5. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94(33):A-2154-2155.

6. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl. Fortbild. Qualitatssich. 2005; 99(8):468–519.

7. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006 + Domäne 8. 2008 [cited: 2017-06-26]. http://www.leitlinien.de/mdb/edocs/pdf/literatur/delbi-fassung-2005-2006-domaene-8-2008.pdf.

8. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012. http://www.awmf.org/leitlinien/awmf-regelwerk.html.

9. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. Version 1. 2017 [cited: 2017-12-20]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.

10. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Leitlinienreport, 5. Auflage. Version 1. 2019 [cited: 2019-03-28]. DOI: 10.6101/AZQ/000441. http://doi.org/10.6101/AZQ/000441.

11. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490–7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.

12. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650):924–6. http://www.ncbi.nlm.nih.gov/pubmed/18436948.

13. Dunham RB. Nominal Group Technique: A Users’ guide. Madison: Wisconsin School of Business; 1998.

14. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Nature 1998; 2(3):i-88. http://www.ncbi.nlm.nih.gov/pubmed/9561895.

15. Kopp IB, Selbmann HK, Koller M. Konsensufindung in evidenzbasierten Leitlinien - vom Mythos zur rationalen Strategie. Z Arztl. Fortbild. Qualitatssich. 2007; 101(2):89–95. DOI: 10.1016/j.zgesun.2007.01.002. http://www.ncbi.nlm.nih.gov/pubmed/17458353.

16. Deutsche Gesellschaft für Kardiologie (DGK). Infarkt-bedingter kardiogener Schock - Diagnose, Monitoring und Therapie. Langfassung. 2010 [cited: 2017-06-26]. http://www.awmf.org/uploads/tx_szleitlinien/019-013l_S3_Infarkt-bedingter_kardiogener_Schock_Diagnose_Monitoring_Therapie_2010-abgelaufen.pdf.

17. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130(25):e344-e426. DOI: 10.1161/CIR.0000000000000134. http://www.ncbi.nlm.nih.gov/pubmed/25249585.

18. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(4):e362-e425. DOI: 10.1161/CIR.0b013e3182742cf6. http://www.ncbi.nlm.nih.gov/pubmed/23247304.

19. Deutsche Gesellschaft für Kardiologie (DGK). ESC Pocket Guidelines. Therapie des akuten Herzinfarktes bei Patienten mit ST-Streckenhebung (STEMI). Version 2017. Grünwald: Bruckmeier; 2018 (Pocket-Leitlinien). https://leitlinien.dgk.org/2018/pocket-leitlinie-therapie-des-akuten-herzinfarktes-bei-patienten-mit-st-streckenhebung-stemi-version-2017/.

20. Deutsche Gesellschaft für Kardiologie (DGK). ESC Pocket Guidelines. Akutes Koronarsyndrom ohne ST-Streckenhebung (NSTE-ACS). Update 2015. Grünwald: Bruckmeier; 2016 (Pocket-Leitlinien). https://leitlinien.dgk.org/2016/pocket-leitlinie-akutes-koronarsyndrom-ohne-st-hebung-nste-acs-version-2015/.

21. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3):267–315. DOI: 10.1093/eurheartj/ehv320. http://www.ncbi.nlm.nih.gov/pubmed/26320110.

22. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2):119–77. DOI: 10.1093/eurheartj/ehx393. http://www.ncbi.nlm.nih.gov/pubmed/28886621.

23. Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. Edinburgh: SIGN; 2016 (SIGN Publications; 148). http://www.sign.ac.uk/sign-148-acute-coronary-syndrome.html.

24. Ludt S, Angelow A, Baum E, et al. Hausärztliche Risikoberatung zur kardiovaskulären Prävention. S3-Leitlinie. AWMF-Register-Nr. 053-024. 2017 (DEGAM-Leitlinie; 19) [cited: 2018-06-11]. http://www.awmf.org/uploads/tx_szleitlinien/053-024l_Hausaerztliche_Risikoberat_kardiovask_Praevention_2017-11_1.pdf.

25. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29):2315–81. DOI: 10.1093/eurheartj/ehw106. http://www.ncbi.nlm.nih.gov/pubmed/27222591.

26. Gesundheitsberichterstattung des Bundes (GBE). Statistik der häufigsten Todesursachen 2003-2013. Abgerufen am 24.03.2015. 2015 [cited: 2015-03-30]. http://www.gbe-bund.de.

27. Gosswald A, Schienkiewitz A, Nowossadeck E, et al. Prävalenz von Herzinfarkt und koronarer Herzkrankheit bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56(5-6):650–5. DOI: 10.1007/s00103-013-1666-9. http://www.ncbi.nlm.nih.gov/pubmed/23703482.

28. Canadian Cardiovascular Society (CCS). Grading of angina. 1976 [cited: 2014-09-09]. http://ccs.ca/images/Guidelines/PositionStatements/Grading_of_Angina.pdf.

29. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38):2949–3003. DOI: 10.1093/eurheartj/eht296. http://www.ncbi.nlm.nih.gov/pubmed/23996286.

30. Verdon F, Herzig L, Burnand B, et al. Chest pain in daily practice: Occurrence, causes and management. Swiss Med Wkly 2008; 138(23-24):340–7. http://www.ncbi.nlm.nih.gov/pubmed/18561039.

31. Bosner S, Becker A, Haasenritter J, et al. Chest pain in primary care: Epidemiology and pre-work-up probabilities. Eur J Gen Pract 2009; 15(3):141–6. DOI: 10.3109/13814780903329528. http://www.ncbi.nlm.nih.gov/pubmed/19883149.

32. Haasenritter J, Bosner S, Vaucher P, et al. Ruling out coronary heart disease in primary care: External validation of a clinical prediction rule. Br J Gen Pract 2012; 62(599):e415-e421. DOI: 10.3399/bjgp12X649106. http://www.ncbi.nlm.nih.gov/pubmed/22687234.

33. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Haasenritter J, Bösner S, et al. Brustschmerz. DEGAM-Leitlinie Nr. 15. Düsseldorf: Omikron Publ; 2011. http://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/LL-15_Langfassung_Brustschmerz.pdf.

34. Deutsche Gesellschaft für Kardiologie (DGK), Zeymer, U., Kastrati A, Rassaf T, et al. ESC Pocket Guidelines. Therapie des akuten Herzinfarktes bei Patienten mit persistierender ST-Streckenhebung. Update 2012. 2012 [cited: 2015-06-09]. http://leitlinien.dgk.org/files/PL_STEMI_Internet_13.pdf.

35. Deutsche Gesellschaft für Kardiologie (DGK), Achenbach S, Hamm CW. ESC Pocket Guidelines. Akutes Koronarsyndrom ohne ST-Hebung (NSTE-ACS). Update 2011. 2012 [cited: 2015-06-09]. http://leitlinien.dgk.org/files/2012_Pocket-Leitlinie_Akutes_Koronarsyndrom_NSTE-ACS.pdf.

36. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(23):2999–3054. DOI: 10.1093/eurheartj/ehr236. http://www.ncbi.nlm.nih.gov/pubmed/21873419.

37. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20):2569–619. DOI: 10.1093/eurheartj/ehs215. http://www.ncbi.nlm.nih.gov/pubmed/22922416.

38. Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. A national clinical guideline. Updated February 2013. Edinburgh: SIGN; 2013 (SIGN Publications; 93). http://www.sign.ac.uk/pdf/sign93.pdf.

39. Cooper A, Calvert N, Skinner J, et al. Chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. London: National Clinical Guideline Centre for Acute and Chronic Conditions; 2010. http://www.nice.org.uk/nicemedia/live/12947/47931/47931.pdf.

40. Bösner S, Becker A, Abu HM, et al. Accuracy of symptoms and signs for coronary heart disease assessed in primary care. Br J Gen Pract 2010; 60(575):e246-e257. http://www.ncbi.nlm.nih.gov/pubmed/20529488.

41. Gencer B, Vaucher P, Herzig L, et al. Ruling out coronary heart disease in primary care patients with chest pain: A clinical prediction score. BMC Med 2010; 8:9. http://www.ncbi.nlm.nih.gov/pubmed/20092615.

42. Herrmann-Lingen C, Buss U. Angst und Depressivität im Verlauf der koronaren Herzkrankheit. Frankfurt/Main: VAS; 2002 (Statuskonferenz Psychokardiologie; 5). http://www.vasverlag.de/product_info.php?info=p231_Angst-und-Depressivitaet-im-Verlauf-der-koronaren-Herzkrankheit---Christoph-Herrmann-Lingen---Ullrich-Buss.html&XTCsid=0437b90aa1a4e4882078a99ccbb9939d.

43. Bosner S, Haasenritter J, Becker A, et al. Ruling out coronary artery disease in primary care: Development and validation of a simple prediction rule. CMAJ 2010; 182(12):1295–300. http://www.ncbi.nlm.nih.gov/pubmed/20603345.

44. Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: Validation, updating, and extension. Eur Heart J 2011; 32(11):1316–30. DOI: 10.1093/eurheartj/ehr014. http://www.ncbi.nlm.nih.gov/pubmed/21367834.

45. Diamond GA, Staniloff HM, Forrester JS, et al. Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary artery disease. J Am Coll Cardiol 1983; 1(2 Pt 1):444–55. http://www.ncbi.nlm.nih.gov/pubmed/6338081.

46. American College of Cardiology Foundation, American College of Radiology, Society of Cardiovascular Computed Tomography (SCCT), et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol 2006; 48(7):1475–97. DOI: 10.1016/j.jacc.2006.07.003. http://www.ncbi.nlm.nih.gov/pubmed/17010819.

47. Skinner JS, Smeeth L, Kendall JM, et al. NICE guidance. Chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart 2010; 96(12):974–8. DOI: 10.1136/hrt.2009.190066. http://www.ncbi.nlm.nih.gov/pubmed/20538674.

48. Chun AA, McGee SR. Bedside diagnosis of coronary artery disease: A systematic review. Am J Med 2004; 117(5):334–43. DOI: 10.1016/j.amjmed.2004.03.021. http://www.ncbi.nlm.nih.gov/pubmed/15336583.

49. Mant J, McManus RJ, Oakes RA, et al. Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care. Health Technol Assess 2004; 8(2):iii1-iii158. http://www.ncbi.nlm.nih.gov/pubmed/14754562.

50. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in colloboration with the American Society of Echocardiography. Circulation 1997; 95(6):1686–744. http://www.ncbi.nlm.nih.gov/pubmed/9118558.

51. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003; 16(10):1091–110. http://www.ncbi.nlm.nih.gov/pubmed/14566308.

52. Garcia MJ, Haines DE, Lai WW, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. J Am Coll Cardiol 2011; 57(9):1126–66. DOI: 10.1016/j.jacc.2010.11.002. http://www.ncbi.nlm.nih.gov/pubmed/21349406.

53. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Langfassung, 2. Auflage. Version 3. 2017 [cited: 2018-04-23]. DOI: 10.6101/AZQ/000405. http://doi.org/10.6101/AZQ/000405.

54. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28(20):2539–50. DOI: 10.1093/eurheartj/ehm037. http://www.ncbi.nlm.nih.gov/pubmed/17428822.

55. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009; 10(2):165–93. DOI: 10.1093/ejechocard/jep007. http://www.ncbi.nlm.nih.gov/pubmed/19270053.

56. Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289(2):194–202. http://www.ncbi.nlm.nih.gov/pubmed/12517230.

57. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23(7):685–713. DOI: 10.1016/j.echo.2010.05.010. http://www.ncbi.nlm.nih.gov/pubmed/20620859.

58. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28):2159–219. DOI: 10.1093/eurheartj/eht151. http://www.ncbi.nlm.nih.gov/pubmed/23771844.

59. Snow V, Barry P, Fihn SD, et al. Evaluation of primary care patients with chronic stable angina: Guidelines from the American College of Physicians. Ann Intern Med 2004; 141(1):57–64. http://www.ncbi.nlm.nih.gov/pubmed/15238371.

60. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22(1):1–23. DOI: 10.1016/j.echo.2008.11.029. http://www.ncbi.nlm.nih.gov/pubmed/19130998.

61. Lancellotti P, Moura L, Pierard LA, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: Mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010; 11(4):307–32. DOI: 10.1093/ejechocard/jeq031. http://www.ncbi.nlm.nih.gov/pubmed/20435783.

62. Visser CA, Kan G, David GK, et al. Echocardiographic-cineangiographic correlation in detecting left ventricular aneurysm: A prospective study of 422 patients. Am. J. Cardiol. 1982; 50(2):337–41. http://www.ncbi.nlm.nih.gov/pubmed/7102561.

63. Knuuti J, Bengel F, Bax JJ, et al. Risks and benefits of cardiac imaging: An analysis of risks related to imaging for coronary artery disease. Eur Heart J 2014; 35(10):633–8. DOI: 10.1093/eurheartj/eht512. http://www.ncbi.nlm.nih.gov/pubmed/24375074.

64. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40(8):1531–40. http://www.ncbi.nlm.nih.gov/pubmed/12392846.

65. Trappe HJ, Lollgen H. Leitlinien zur Ergometrie. Z Kardiol 2000; 89(9):821–31. http://www.ncbi.nlm.nih.gov/pubmed/11077695.

66. Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001; 344(24):1840–5. http://www.ncbi.nlm.nih.gov/pubmed/11407346.

67. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989; 80(1):87–98. http://www.ncbi.nlm.nih.gov/pubmed/2661056.

68. Banerjee A, Newman DR, van den Bruel A, et al. Diagnostic accuracy of exercise stress testing for coronary artery disease: A systematic review and meta-analysis of prospective studies. Int J Clin Pract 2012; 66(5):477–92. DOI: 10.1111/j.1742-1241.2012.02900.x. http://www.ncbi.nlm.nih.gov/pubmed/22512607.

69. Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am. J. Cardiol. 1999; 83(5):660–6. http://www.ncbi.nlm.nih.gov/pubmed/10080415.

70. Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr. 2008; 9(4):415–37. DOI: 10.1093/ejechocard/jen175. http://www.ncbi.nlm.nih.gov/pubmed/18579481.

71. Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20(9):1021–41. DOI: 10.1016/j.echo.2007.07.003. http://www.ncbi.nlm.nih.gov/pubmed/17765820.

72. Jong MC de, Genders TS, van Geuns RJ, et al. Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: A systematic review and meta-analysis. Eur Radiol 2012; 22(9):1881–95. DOI: 10.1007/s00330-012-2434-1. http://www.ncbi.nlm.nih.gov/pubmed/22527375.

73. Metz LD, Beattie M, Hom R, et al. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: A meta-analysis. J Am Coll Cardiol 2007; 49(2):227–37. DOI: 10.1016/j.jacc.2006.08.048. http://www.ncbi.nlm.nih.gov/pubmed/17222734.

74. Deutsche Gesellschaft für Nuklearmedizin (DGN), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Bengel F, et al. Myokard-Perfusions-Szintigraphie. 2012 [cited: 2015-01-06]. http://www.awmf.org/uploads/tx_szleitlinien/031-006l_S1_Myokard_Perfusions-Szintigraphie_2012-05_01.pdf.

75. Chen L, Wang X, Bao J, et al. Direct comparison of cardiovascular magnetic resonance and single-photon emission computed tomography for detection of coronary artery disease: A meta-analysis. PLoS. One. 2014; 9(2):e88402. DOI: 10.1371/journal.pone.0088402. http://www.ncbi.nlm.nih.gov/pubmed/24520382.

76. Parker MW, Iskandar A, Limone B, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: A bivariate meta-analysis. Circ Cardiovasc Imaging 2012; 5(6):700–7. DOI: 10.1161/CIRCIMAGING.112.978270. http://www.ncbi.nlm.nih.gov/pubmed/23051888.

77. Zhou T, Yang LF, Zhai JL, et al. SPECT myocardial perfusion versus fractional flow reserve for evaluation of functional ischemia: A meta analysis. Eur J Radiol 2014; 83(6):951–6. DOI: 10.1016/j.ejrad.2014.02.018. http://www.ncbi.nlm.nih.gov/pubmed/24666512.

78. Kramer CM, Barkhausen J, Flamm SD, et al. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc. Magn Reson. 2013; 15:91. DOI: 10.1186/1532-429X-15-91. http://www.ncbi.nlm.nih.gov/pubmed/24103764.

79. Desai RR, Jha S. Diagnostic performance of cardiac stress perfusion MRI in the detection of coronary artery disease using fractional flow reserve as the reference standard: A meta-analysis. AJR Am J Roentgenol 2013; 201(2):W245-W252. DOI: 10.2214/AJR.12.10002. http://www.ncbi.nlm.nih.gov/pubmed/23883239.

80. Iwata K, Nakagawa S, Ogasawara K. The prognostic value of normal stress cardiovascular magnetic resonance imaging. J Comput. Assist. Tomogr. 2014; 38(1):36–43. DOI: 10.1097/RCT.0b013e3182a474a0. http://www.ncbi.nlm.nih.gov/pubmed/24424555.

81. Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: A meta-analysis. J Am Coll Cardiol 2007; 50(14):1343–53. http://www.ncbi.nlm.nih.gov/pubmed/17903634.

82. Achenbach S, Barkhausen J, Beer M, et al. Konsensusempfehlungen der DRG/DGK/DGPK zum Einsatz der Herzbildgebung mit Computertomografie und Magnetresonanztomografie. Rofo 2012; 184(4):345–68. http://www.ncbi.nlm.nih.gov/pubmed/22426867.

83. Abbara S, Arbab-Zadeh A, Callister TQ, et al. SCCT guidelines for performance of coronary computed tomographic angiography: A report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr 2009; 3(3):190–204. DOI: 10.1016/j.jcct.2009.03.004. http://www.ncbi.nlm.nih.gov/pubmed/19409872.

84. Halliburton SS, Abbara S, Chen MY, et al. SCCT guidelines on radiation dose and dose-optimization strategies in cardiovascular CT. J Cardiovasc Comput Tomogr 2011; 5(4):198–224. DOI: 10.1016/j.jcct.2011.06.001. http://www.ncbi.nlm.nih.gov/pubmed/21723512.

85. Li S, Ni Q, Wu H, et al. Diagnostic accuracy of 320-slice computed tomography angiography for detection of coronary artery stenosis: Meta-analysis. Int J Cardiol 2013; 168(3):2699–705. DOI: 10.1016/j.ijcard.2013.03.023. http://www.ncbi.nlm.nih.gov/pubmed/23566493.

86. Powell H, Cosson P. Comparison of 64-slice computed tomography angiography and coronary angiography for the detection and assessment of coronary artery disease in patients with angina: A systematic review. Radiogr 2013; 19(2):168–75. DOI: 10.1016/j.radi.2012.12.005.

87. Gorenoi V, Schonermark MP, Hagen A. CT coronary angiography vs. invasive coronary angiography in CHD. GMS Health Technol Assess 2012; 8:Doc02. DOI: 10.3205/hta000100. http://www.ncbi.nlm.nih.gov/pubmed/22536300.

88. Ballmoos MW von, Haring B, Juillerat P, et al. Meta-analysis: Diagnostic performance of low-radiation-dose coronary computed tomography angiography. Ann Intern Med 2011; 154(6):413–20. DOI: 10.1059/0003-4819-154-6-201103150-00007. http://www.ncbi.nlm.nih.gov/pubmed/21403076.

89. Sarno G, Decraemer I, Vanhoenacker PK, et al. On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: A comparison with invasive angiography. JACC. Cardiovasc Interv. 2009; 2(6):550–7. DOI: 10.1016/j.jcin.2009.03.009. http://www.ncbi.nlm.nih.gov/pubmed/19539260.

90. Nielsen LH, Ortner N, Norgaard BL, et al. The diagnostic accuracy and outcomes after coronary computed tomography angiography vs. conventional functional testing in patients with stable angina pectoris: A systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2014; 15(9):961–71. DOI: 10.1093/ehjci/jeu027. http://www.ncbi.nlm.nih.gov/pubmed/24618659.

91. Habib PJ, Green J, Butterfield RC, et al. Association of cardiac events with coronary artery disease detected by 64-slice or greater coronary CT angiography: A systematic review and meta-analysis. Int J Cardiol 2013; 169(2):112–20. DOI: 10.1016/j.ijcard.2013.08.096. http://www.ncbi.nlm.nih.gov/pubmed/24090745.

92. Bundesamt für Strahlenschutz (BfS). Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für diagnostische und interventionelle Röntgenuntersuchungen. 2010 [cited: 2017-06-26]. http://www.bfs.de/SharedDocs/Downloads/BfS/DE/fachinfo/ion/drw-roentgen.pdf?__blob=publicationFile&v=1.

93. Bundesamt für Strahlenschutz (BfS). Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für nuklearmedizinische Untersuchungen. 2012 [cited: 2017-06-26]. http://www.laekb.de/files/1456FC3088F/Referenzwerte_Nuklearmedizin.pdf.

94. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2014; 130(19):1749–67. DOI: 10.1161/CIR.0000000000000095. http://www.ncbi.nlm.nih.gov/pubmed/25070666.

95. National Institute for Health and Care Excellence (NICE). Management of stable angina. Last modified: December 2012. London: NICE; 2011 (NICE Clinical Guideline; 126). http://www.nice.org.uk/guidance/cg126/resources/guidance-management-of-stable-angina-pdf.

96. Perk J, Backer G de, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33(13):1635–701. DOI: 10.1093/eurheartj/ehs092. http://www.ncbi.nlm.nih.gov/pubmed/22555213.

97. Ladwig KH, Lederbogen F, Albus C, et al. Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie. Update 2013. Der Kardiologe 2013; 7(1):7–27. DOI: 10.1007/s12181-012-0478-8.

98. Gohlke H, Albus C, Bönner G, et al. CME Zertifizierte Fortbildung. Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Teil 4: Thrombozytenfunktionshemmer, Hormonersatztherapie, Verhaltensänderung und psychosoziale Risikofaktoren. Der Kardiologe 2013; 7(4):297–306. DOI: 10.1007/s12181-012-0469-9.

99. Albus C, Ladwig KH, Herrmann-Lingen C. Psychokardiologie: Praxisrelevante Erkenntnisse und Handlungsempfehlungen. Dtsch Med Wochenschr 2014; 139(12):596–601. DOI: 10.1055/s-0033-1360102. http://www.ncbi.nlm.nih.gov/pubmed/24619718.

100. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: Systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014; 129(12):1350–69. DOI: 10.1161/CIR.0000000000000019. http://www.ncbi.nlm.nih.gov/pubmed/24566200.

101. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: A meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006; 27(23):2763–74. DOI: 10.1093/eurheartj/ehl338. http://www.ncbi.nlm.nih.gov/pubmed/17082208.

102. Rutledge T, Redwine LS, Linke SE, et al. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013; 75(4):335–49. DOI: 10.1097/PSY.0b013e318291d798. http://www.ncbi.nlm.nih.gov/pubmed/23630306.

103. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 5. 2015 [cited: 2018-06-06]. DOI: 10.6101/AZQ/000364. http://doi.org/10.6101/AZQ/000364.

104. Tonne C, Schwartz J, Mittleman M, et al. Long-term survival after acute myocardial infarction is lower in more deprived neighborhoods. Circulation 2005; 111(23):3063–70. DOI: 10.1161/CIRCULATIONAHA.104.496174. http://www.ncbi.nlm.nih.gov/pubmed/15939820.

105. Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. JAMA 2010; 303(12):1159–66. DOI: 10.1001/jama.2010.297. http://www.ncbi.nlm.nih.gov/pubmed/20332401.

106. Alter DA, Franklin B, Ko DT, et al. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS. One. 2014; 8(6):e65130. DOI: 10.1371/journal.pone.0065130. http://www.ncbi.nlm.nih.gov/pubmed/23755180.

107. Barth J, Schneider S, Känel R von. Lack of social support in the etiology and the prognosis of coronary heart disease: A systematic review and meta-analysis. Psychosom Med 2010; 72(3):229–38. DOI: 10.1097/PSY.0b013e3181d01611. http://www.ncbi.nlm.nih.gov/pubmed/20223926.

108. Richardson S, Shaffer JA, Falzon L, et al. Meta-analysis of perceived stress and its association with incident coronary heart disease. Am. J. Cardiol. 2012; 110(12):1711–6. DOI: 10.1016/j.amjcard.2012.08.004. http://www.ncbi.nlm.nih.gov/pubmed/22975465.

109. Virtanen M, Ferrie JE, Singh-Manoux A, et al. Overtime work and incident coronary heart disease: The Whitehall II prospective cohort study. Eur Heart J 2010; 31(14):1737–44. DOI: 10.1093/eurheartj/ehq124. http://www.ncbi.nlm.nih.gov/pubmed/20460389.

110. Eller NH, Netterstrom B, Gyntelberg F, et al. Work-related psychosocial factors and the development of ischemic heart disease: A systematic review. Cardiol Rev 2009; 17(2):83–97. DOI: 10.1097/CRD.0b013e318198c8e9. http://www.ncbi.nlm.nih.gov/pubmed/19367150.

111. Orth-Gomer K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA 2000; 284(23):3008–14. http://www.ncbi.nlm.nih.gov/pubmed/11122587.

112. Roest AM, Martens EJ, Jonge P de, et al. Anxiety and risk of incident coronary heart disease: A meta-analysis. J Am Coll Cardiol 2010; 56(1):38–46. DOI: 10.1016/j.jacc.2010.03.034. http://www.ncbi.nlm.nih.gov/pubmed/20620715.

113. Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: A meta-analysis. Psychosom Med 2010; 72(6):563–9. DOI: 10.1097/PSY.0b013e3181dbff97. http://www.ncbi.nlm.nih.gov/pubmed/20410247.

114. Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. Am Heart J 2013; 166(5):806–14. DOI: 10.1016/j.ahj.2013.07.031. http://www.ncbi.nlm.nih.gov/pubmed/24176435.

115. Edmondson D, Richardson S, Falzon L, et al. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: A meta-analytic review. PLoS. One. 2012; 7(6):e38915. DOI: 10.1371/journal.pone.0038915. http://www.ncbi.nlm.nih.gov/pubmed/22745687.

116. Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: A meta-analysis of thirteen cohort studies. J Psychiatr Res 2013; 47(11):1549–56. DOI: 10.1016/j.jpsychires.2013.07.011. http://www.ncbi.nlm.nih.gov/pubmed/23953755.

117. Walker ER, McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. JAMA Psychiatry 2015; 72(4):334–41. DOI: 10.1001/jamapsychiatry.2014.2502. http://www.ncbi.nlm.nih.gov/pubmed/25671328.

118. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: A meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53(11):936–46. DOI: 10.1016/j.jacc.2008.11.044. http://www.ncbi.nlm.nih.gov/pubmed/19281923.

119. Grande G, Romppel M, Barth J. Association between type D personality and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis. Ann Behav Med 2012; 43(3):299–310. DOI: 10.1007/s12160-011-9339-0. http://www.ncbi.nlm.nih.gov/pubmed/22237826.

120. Bandelow B, Wiltink J, Alpers GW, et al. S3-Leitlinie Behandlung von Angststörungen. Kurzversion. 2014 [cited: 2017-06-26]. http://www.awmf.org/uploads/tx_szleitlinien/051-028k_S3_Angstst%C3%B6rungen_2014-05_1.pdf.

121. Deutschsprachige Gesellschaft für Psychotraumatologie (DeGPT), Deutsche Gesellschaft für Psychotherapeutische Medizin und ärztliche Psychotherapie (DGPM), Deutsches Kollegium für Psychosomatische Medizin (DKPM), et al. S3-Leitlinie. Posttraumatische Belastungsstörung. ICD 10: F 43.1. 2011 [cited: 2019-03-07]. https://www.awmf.org/uploads/tx_szleitlinien/051-010l_S3_Posttraumatische_Belastungsstoerung_2012-abgelaufen.pdf.

122. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff; 2006 (S3 Praxisleitlinien in Psychiatrie und Psychotherapie; 1).

123. Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107(23):2900–7. http://www.ncbi.nlm.nih.gov/pubmed/12771008.

124. New York University School of Medicine (NYU). International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA). 2015 [cited: 2019-03-18]. https://clinicaltrials.gov/ct2/show/record/NCT01471522.

125. Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): Mode-of-death results. JACC Heart Fail 2013; 1(5):400–8. DOI: 10.1016/j.jchf.2013.04.012. http://www.ncbi.nlm.nih.gov/pubmed/24621972.

126. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14(8):803–69. DOI: 10.1093/eurjhf/hfs105. http://www.ncbi.nlm.nih.gov/pubmed/22828712.

127. Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015; 22(2):229–45. DOI: 10.1007/s12350-015-0096-5. http://www.ncbi.nlm.nih.gov/pubmed/25733105.

128. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473–83. http://www.ncbi.nlm.nih.gov/pubmed/1593914.

129. Morfeld M, Kirchberger I, Bullinger M. SF-36. Fragebogen zum Gesundheitszustand. 2nd ed. Göttingen: Hogrefe; 2011.

130. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25(2):333–41. http://www.ncbi.nlm.nih.gov/pubmed/7829785.

131. Höfer S, Benzer W, Schüssler G, et al. Health-related quality of life in patients with coronary artery disease treated for angina: Validity and reliability of German translations of two specific questionnaires. Qual Life Res 2003; 12(2):199–212. http://www.ncbi.nlm.nih.gov/pubmed/12639066.

132. Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3):220–33. http://www.ncbi.nlm.nih.gov/pubmed/8628042.

133. Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am. J. Cardiol. 1991; 67(13):1084–9. http://www.ncbi.nlm.nih.gov/pubmed/2024598.

134. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3):199–208. http://www.ncbi.nlm.nih.gov/pubmed/10109801.

135. Siegrist J, Broer M, Junge A. PLC. Profil der Lebensqualität chronisch Kranker. Göttingen: Hogrefe; 1995.

136. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: A meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38):2940–8. DOI: 10.1093/eurheartj/eht295. http://www.ncbi.nlm.nih.gov/pubmed/23907142.

137. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients. Am J Med 2012; 125(9):882–7. DOI: 10.1016/j.amjmed.2011.12.013. http://www.ncbi.nlm.nih.gov/pubmed/22748400.

138. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation 2009; 119(23):3028–35. DOI: 10.1161/CIRCULATIONAHA.108.768986. http://www.ncbi.nlm.nih.gov/pubmed/19528344.

139. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5):487–97. DOI: 10.1056/NEJMra050100. http://www.ncbi.nlm.nih.gov/pubmed/16079372.

140. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: A systematic review. Arch. Intern. Med 2007; 167(6):540–50. http://www.ncbi.nlm.nih.gov/pubmed/17389285.

141. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4):766–74. DOI: 10.1097/HJH.0b013e32835e2286. http://www.ncbi.nlm.nih.gov/pubmed/23337469.

142. Loh A, Simon D, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen - Effekte der Partizipativen Entscheidungsfindung aus systematischen Reviews. Dtsch Arztebl 2007; 104:A-1483-88.

143. Bundesministerium der Justiz und für Verbraucherschutz (BMJV). § 630e Aufklärungspflichten. In: Bundesministerium der Justiz und für Verbraucherschutz (BMJV), editor. Bürgerliches Gesetzbuch (BGB); 2017.

144. Elwyn G, Edwards A, Mowle S, et al. Measuring the involvement of patients in shared decision-making: A systematic review of instruments. Patient Educ Couns. 2001; 43(1):5–22. http://www.ncbi.nlm.nih.gov/pubmed/11311834.

145. Härter M, Loh A, Spies C. Gemeinsam entscheiden-erfolgreich behandeln. Neue Wege für Ärzte und Patienten im Gesundheitswesen. Köln: Dt. Ärzte-Verl.; 2005.

146. Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Ein Positionspapier des Deutschen Netzwerks Evidenzbasierte Medizin. Version 2.0. 2015 [cited: 2017-10-17]. http://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf.

147. Sänger S, Lang B, Klemperer D, et al. Manual Patienteninformation. Empfehlungen zur Erstellung evidenzbasierter Patienteninformationen. Berlin: ÄZQ; 2006 (äzq Schriftenreihe; 25). http://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe25.pdf.

148. Elwyn G, O‘Connor AM, Bennett C, et al. Assessing the Quality of Decision Support Technologies Using the International Patient Decision Aid Standards instrument (IPDASi). PLoS. One. 2009; 4(3):e4705. DOI: 10.1371/journal.pone.0004705.

149. Barlow J, Wright C, Sheasby J, et al. Self-management approaches for people with chronic conditions: A review. Patient Educ Couns. 2002; 48(2):177–87. http://www.ncbi.nlm.nih.gov/pubmed/12401421.

150. McGillion M, O’Keefe-McCarthy S, Carroll SL, et al. Impact of self-management interventions on stable angina symptoms and health-related quality of life: A meta-analysis. BMC Cardiovasc Disord 2014; 14:14. DOI: 10.1186/1471-2261-14-14. http://www.ncbi.nlm.nih.gov/pubmed/24483947.

151. Scherer M, Wagner H.O., Lühmann D, et al. Multimorbidität. S3-Leitlinie. AWMF-Register-Nr. 053-047. 2017 (DEGAM-Leitlinie; 20) [cited: 2018-06-06]. http://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053-047_Multimorbiditaet/053-047l_%20Multimorbiditaet_redakt_24-1-18.pdf.

152. Kotseva K, Wood D, Bacquer D de, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23(6):636–48. DOI: 10.1177/2047487315569401. http://www.ncbi.nlm.nih.gov/pubmed/25687109.

153. Martin LR, M DR, editors. The Oxford handbook of health communication, behavior change, and treatment adherence. New York: Oxford Univ. Pr; 2014.

154. Rubak S, Sandbaek A, Lauritzen T, et al. Motivational interviewing: A systematic review and meta-analysis. Br J Gen Pract 2005; 55(513):305–12. http://www.ncbi.nlm.nih.gov/pubmed/15826439.

155. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: A scientific statement from the American Heart Association. Circulation 2010; 122(4):406–41. DOI: 10.1161/CIR.0b013e3181e8edf1. http://www.ncbi.nlm.nih.gov/pubmed/20625115.

156. Deutsche Gesellschaft für Prävention und Rehabilitationvon Herz-Kreislauferkrankungen (DGPR), Bjarnason-Weherns B. Leitlinie körperliche Aktivität zur Sekundärprävention und Therapie kardiovaskulärer Erkrankungen. Clin Res Cardiol. Suppl 2009; 4(4 Suppl):1–44. DOI: 10.1007/s11789-009-0078-8.

157. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: A scientific statement from the American Heart Association. Circulation 2013; 128(8):873–934. DOI: 10.1161/CIR.0b013e31829b5b44. http://www.ncbi.nlm.nih.gov/pubmed/23877260.

158. Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016(1):CD001800. DOI: 10.1002/14651858.CD001800.pub3. http://www.ncbi.nlm.nih.gov/pubmed/26730878.

159. Sixt S, Beer S, Bluher M, et al. Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. Eur Heart J 2010; 31(1):112–9. DOI: 10.1093/eurheartj/ehp398. http://www.ncbi.nlm.nih.gov/pubmed/19793768.

160. Ponikowski P, Anker S, Voors AA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2016: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Developed with the special contribution Heart Failure Association (HFA) of the ESC. 2016 [cited: 2017-03-30]. http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure.

161. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014(4):CD003331. DOI: 10.1002/14651858.CD003331.pub4. http://www.ncbi.nlm.nih.gov/pubmed/24771460.

162. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: Definitions and distinctions for health-related research. Public health reports (Washington, D.C. 1974) 1985; 100(2):126–31. http://www.ncbi.nlm.nih.gov/pubmed/3920711.

163. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: An update of activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32(9 Suppl):S498-S504. http://www.ncbi.nlm.nih.gov/pubmed/10993420.

164. Norton K, Norton L, Sadgrove D. Position statement on physical activity and exercise intensity terminology. J Sci Med Sport 2010; 13(5):496–502. DOI: 10.1016/j.jsams.2009.09.008. http://www.ncbi.nlm.nih.gov/pubmed/20005170.

165. Ross R, Blair SN, Arena R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation 2016; 134(24):e653-e699. DOI: 10.1161/CIR.0000000000000461. http://www.ncbi.nlm.nih.gov/pubmed/27881567.

166. Deutsche Gesellschaft für Kardiologie (DGK), Gohlke H, Gielen S, et al. ESC Pocketguideline Prävention von Herz-Kreislauferkrankungen. 2012 [cited: 2016-08-30]. http://leitlinien.dgk.org/files/PL_Pr%C3%A4vention_Internet_13.pdf.

167. Jakobsen MU, O‘Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: A pooled analysis of 11 cohort studies. Am J Clin Nutr 2009; 89(5):1425–32. DOI: 10.3945/ajcn.2008.27124. http://www.ncbi.nlm.nih.gov/pubmed/19211817.

168. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: A systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010; 7(3):e1000252. http://www.ncbi.nlm.nih.gov/pubmed/20351774.

169. Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: Where does the evidence stand in 2010? Am J Clin Nutr 2011; 93(4):684–8. DOI: 10.3945/ajcn.110.004622. http://www.ncbi.nlm.nih.gov/pubmed/21270379.

170. Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med 2006; 354(15):1601–13. DOI: 10.1056/NEJMra054035. http://www.ncbi.nlm.nih.gov/pubmed/16611951.

171. Mozaffarian D, Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr 2009; 63(2 Suppl):S22-S33. DOI: 10.1038/sj.ejcn.1602976. http://www.ncbi.nlm.nih.gov/pubmed/19424216.

172. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: Systematic review and meta-analysis. BMJ 2013; 347:f6879. http://www.ncbi.nlm.nih.gov/pubmed/24355537.

173. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1):3–10. http://www.ncbi.nlm.nih.gov/pubmed/11136953.

174. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: Systematic review and meta-analyses. BMJ 2013; 346:f1378. http://www.ncbi.nlm.nih.gov/pubmed/23558164.

175. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: Systematic review and dose-response meta-analysis of prospective cohort studies. BMJ 2014; 349:g4490. http://www.ncbi.nlm.nih.gov/pubmed/25073782.

176. Zheng J, Huang T, Yu Y, et al. Fish consumption and CHD mortality: An updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012; 15(4):725–37. DOI: 10.1017/S1368980011002254. http://www.ncbi.nlm.nih.gov/pubmed/21914258.

177. Luo C, Zhang Y, Ding Y, et al. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: A systematic review and meta-analysis. Am J Clin Nutr 2014; 100(1):256–69. DOI: 10.3945/ajcn.113.076109. http://www.ncbi.nlm.nih.gov/pubmed/24847854.

178. Fung TT, Malik V, Rexrode KM, et al. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr 2009; 89(4):1037–42. DOI: 10.3945/ajcn.2008.27140. http://www.ncbi.nlm.nih.gov/pubmed/19211821.

179. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: Systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014; 348:g1903. http://www.ncbi.nlm.nih.gov/pubmed/24690623.

180. Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92(5):1189–96. DOI: 10.3945/ajcn.2010.29673. http://www.ncbi.nlm.nih.gov/pubmed/20810976.

181. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018; 378(25):e34. DOI: 10.1056/NEJMoa1800389. http://www.ncbi.nlm.nih.gov/pubmed/29897866.

182. Mensink GB, Schienkiewitz A, Haftenberger M, et al. Übergewicht und Adipositas in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013; 56(5-6):786–94. DOI: 10.1007/s00103-012-1656-3. http://www.ncbi.nlm.nih.gov/pubmed/23703499.

183. Wormser D, Kaptoge S, Di AE, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: Collaborative analysis of 58 prospective studies. Lancet 2011; 377(9771):1085–95. http://www.ncbi.nlm.nih.gov/pubmed/21397319.

184. Oreopoulos A, Padwal R, Norris CM, et al. Effect of obesity on short- and long-term mortality postcoronary revascularization: A meta-analysis. Obesity (Silver. Spring) 2008; 16(2):442–50. DOI: 10.1038/oby.2007.36. http://www.ncbi.nlm.nih.gov/pubmed/18239657.

185. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic review of cohort studies. Lancet 2006; 368(9536):666–78. DOI: 10.1016/S0140-6736(06)69251-9. http://www.ncbi.nlm.nih.gov/pubmed/16920472.

186. Pack QR, Rodriguez-Escudero JP, Thomas RJ, et al. The prognostic importance of weight loss in coronary artery disease: A systematic review and meta-analysis. Mayo Clin Proc 2014; 89(10):1368–77. DOI: 10.1016/j.mayocp.2014.04.033. http://www.ncbi.nlm.nih.gov/pubmed/25199859.

187. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369(2):145–54. DOI: 10.1056/NEJMoa1212914. http://www.ncbi.nlm.nih.gov/pubmed/23796131.

188. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen. 2016 [cited: 2018-01-17]. DOI: 10.1007/978-3-662-47086-2. http://www.awmf.org/uploads/tx_szleitlinien/076-001l_S3-Leitlinie_Alkohol_2016-02.pdf.

189. Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. BMJ 2011; 342:d671. http://www.ncbi.nlm.nih.gov/pubmed/21343207.

190. Costanzo S, Di Castelnuovo A, Donati MB, et al. Alcohol consumption and mortality in patients with cardiovascular disease: A meta-analysis. J Am Coll Cardiol 2010; 55(13):1339–47. DOI: 10.1016/j.jacc.2010.01.006. http://www.ncbi.nlm.nih.gov/pubmed/20338495.

191. He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies. N Engl J Med 1999; 340(12):920–6. DOI: 10.1056/NEJM199903253401204. http://www.ncbi.nlm.nih.gov/pubmed/10089185.

192. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: An evaluation of the evidence. BMJ 1997; 315(7114):973–80. http://www.ncbi.nlm.nih.gov/pubmed/9365294.

193. Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health 2002; 56(9):702–6. http://www.ncbi.nlm.nih.gov/pubmed/12177089.

194. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004; 328(7455):1519. http://www.ncbi.nlm.nih.gov/pubmed/15213107.

195. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie „Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums“. AWMF-Register Nr. 076-006. (Stand: 09.02.2015). 2014 [cited: 2018-09-13]. http://www.awmf.org/uploads/tx_szleitlinien/076-006l_S3_Tabak_2015-02.pdf.

196. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003; 290(1):86–97. DOI: 10.1001/jama.290.1.86. http://www.ncbi.nlm.nih.gov/pubmed/12837716.

197. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121(6):750–8. DOI: 10.1161/CIRCULATIONAHA.109.891523. http://www.ncbi.nlm.nih.gov/pubmed/20124123.

198. U.S. Department of Health and Human Services, Fiore MC, Jaén CR, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. 2008 [cited: 2017-04-20]. http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/update/treating_tobacco_use08.pdf.

199. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60(24):e44-e164. DOI: 10.1016/j.jacc.2012.07.013. http://www.ncbi.nlm.nih.gov/pubmed/23182125.

200. McRobbie H, Bullen C, Glover M, et al. New Zealand smoking cessation guidelines. N Z Med J 2008; 121(1276):57–70. http://www.ncbi.nlm.nih.gov/pubmed/18574510.

201. Richards SH, Anderson L, Jenkinson CE, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2017; 4:CD002902. DOI: 10.1002/14651858.CD002902.pub4. http://www.ncbi.nlm.nih.gov/pubmed/28452408.

202. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321(6):406–12. http://www.ncbi.nlm.nih.gov/pubmed/2473403.

203. Dwight MM, Stoudemire A. Effects of depressive disorders on coronary artery disease: A review. Harv Rev Psychiatry 1997; 5(3):115–22. http://www.ncbi.nlm.nih.gov/pubmed/9385031.

204. Rollman BL, Belnap BH, LeMenager MS, et al. The Bypassing the Blues treatment protocol: Stepped collaborative care for treating post-CABG depression. Psychosom Med 2009; 71(2):217–30. DOI: 10.1097/PSY.0b013e3181970c1c. http://www.ncbi.nlm.nih.gov/pubmed/19188529.

205. Katon WJ, Lin EH, Von KM, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010; 363(27):2611–20. DOI: 10.1056/NEJMoa1003955. http://www.ncbi.nlm.nih.gov/pubmed/21190455.

206. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: Coronary psychosocial evaluation studies randomized controlled trial. Arch. Intern. Med 2010; 170(7):600–8. DOI: 10.1001/archinternmed.2010.29. http://www.ncbi.nlm.nih.gov/pubmed/20386003.

207. Davidson KW, Bigger JT, Burg MM, et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Intern Med 2013; 173(11):997–1004. DOI: 10.1001/jamainternmed.2013.915. http://www.ncbi.nlm.nih.gov/pubmed/23471421.

208. Huffman JC, Mastromauro CA, Beach SR, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: The Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med 2014; 174(6):927–35. DOI: 10.1001/jamainternmed.2014.739. http://www.ncbi.nlm.nih.gov/pubmed/24733277.

209. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65(8):805–15. DOI: 10.1016/j.jacc.2014.11.053. http://www.ncbi.nlm.nih.gov/pubmed/25720624.

210. Chieffo A, Meliga E, Latib A, et al. Drug-eluting stent for left main coronary artery disease. The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC. Cardiovasc Interv. 2012; 5(7):718–27. DOI: 10.1016/j.jcin.2012.03.022. http://www.ncbi.nlm.nih.gov/pubmed/22814776.

211. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Postgrad. Med 2005; Spec No:1–111. http://www.ncbi.nlm.nih.gov/pubmed/17203560.

212. Urban P, Meredith IT, Abizaid A, et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med 2015; 373(21):2038–47. DOI: 10.1056/NEJMoa1503943. http://www.ncbi.nlm.nih.gov/pubmed/26466021.

213. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials. Lancet 2018; 392(10145):387–99. DOI: 10.1016/S0140-6736(18)31133-4. http://www.ncbi.nlm.nih.gov/pubmed/30017552.

214. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324(7329):71–86. http://www.ncbi.nlm.nih.gov/pubmed/11786451.

215. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678):1849–60. http://www.ncbi.nlm.nih.gov/pubmed/19482214.

216. National Institute for Health and Care Excellence (NICE). Stable angina; 2011 (NICE Clinical Guideline; 126). http://www.nice.org.uk/guidance/cg126/evidence/full-guideline-pdf-183176605.

217. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14):1319–30. DOI: 10.1056/NEJMoa1709118. http://www.ncbi.nlm.nih.gov/pubmed/28844192.

218. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352(3):238–44. http://www.ncbi.nlm.nih.gov/pubmed/15659723.

219. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen. Abschlussbericht. Auftrag A04-01A. Version 1.0. 2006 [cited: 2019-02-20]. http://www.iqwig.de/download/A04-01A_Abschlussbericht_Clopidogrel_versus_ASS_in_der_Sekundaerprophylaxe.pdf.

220. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347(13):969–74. http://www.ncbi.nlm.nih.gov/pubmed/12324552.

221. Cosmi B, Rubboli A, Castelvetri C, et al. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001(4):CD002133. DOI: 10.1002/14651858.CD002133. http://www.ncbi.nlm.nih.gov/pubmed/11687144.

222. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102(6):624–9. http://www.ncbi.nlm.nih.gov/pubmed/10931801.

223. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104(5):539–43. http://www.ncbi.nlm.nih.gov/pubmed/11479250.

224. Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101(6):590–3. http://www.ncbi.nlm.nih.gov/pubmed/10673248.

225. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39(1):9–14. http://www.ncbi.nlm.nih.gov/pubmed/11755280.

226. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111(25):3366–73. DOI: 10.1161/CIRCULATIONAHA.104.502815. http://www.ncbi.nlm.nih.gov/pubmed/15967851.

227. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59(24):2159–64. DOI: 10.1016/j.jacc.2012.02.026. http://www.ncbi.nlm.nih.gov/pubmed/22520250.

228. Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78(7):1684–92. http://www.ncbi.nlm.nih.gov/pubmed/24759796.

229. Agarwal N, Jain A, Mahmoud AN, et al. Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. Am J Med 2017; 130(11):1280–9. DOI: 10.1016/j.amjmed.2017.03.057. http://www.ncbi.nlm.nih.gov/pubmed/28460853.

230. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377(16):1513–24. DOI: 10.1056/NEJMoa1708454. http://www.ncbi.nlm.nih.gov/pubmed/28844193.

231. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375(25):2423–34. DOI: 10.1056/NEJMoa1611594. http://www.ncbi.nlm.nih.gov/pubmed/27959713.

232. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381(9872):1107–15. DOI: 10.1016/S0140-6736(12)62177-1. http://www.ncbi.nlm.nih.gov/pubmed/23415013.

233. Verma S, Goodman SG, Mehta SR, et al. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg 2015; 15:112. DOI: 10.1186/s12893-015-0096-z. http://www.ncbi.nlm.nih.gov/pubmed/26467661.

234. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel plus Acetylsalicylsäure bei akutem Koronarsyndrom. Auftrag A04-01B. Version 1.0. 2009 (IQWiG-Berichte; 43) [cited: 2018-02-05]. http://www.iqwig.de/download/A04-01B_AB_Clopidogrel_plus_ASS_bei_akutem_Koronarsyndrom.pdf.

235. MSD Sharp und Dohme. Die Behandlung mit Tredaptive (Nicotinsäure/Laropiprant, MSD) muss beendet werden. 2013 (Rote-Hand-Briefe) [cited: 2018-05-15]. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2013/20130121.pdf.

236. National Institute for Health and Care Excellence (NICE), Wierzbicki A, Ahmad R, et al. Lipid Modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.Nice clinical guideline CG 181. 2014 (NICE Clinical Guideline; 181) [cited: 2016-04-21]. http://www.nice.org.uk/guidance/cg181/evidence/lipid-modification-update-full-guideline-243786637.

237. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493):1267–78. http://www.ncbi.nlm.nih.gov/pubmed/16214597.

238. Cholesterol Treatment Trialists’ Ctt Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670–81. http://www.ncbi.nlm.nih.gov/pubmed/21067804.

239. Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017; 389(10088):2473–81. DOI: 10.1016/S0140-6736(17)31075-9. http://www.ncbi.nlm.nih.gov/pubmed/28476288.

240. Landmesser U, Chapman MJ, Farnier M, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2016; 38(29):2245–55. DOI: 10.1093/eurheartj/ehw480. http://www.ncbi.nlm.nih.gov/pubmed/27789571.

241. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 Suppl 2):S1-45. DOI: 10.1161/01.cir.0000437738.63853.7a. http://www.ncbi.nlm.nih.gov/pubmed/24222016.

242. Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385(9976):1397–405. DOI: 10.1016/S0140-6736(14)61368-4. http://www.ncbi.nlm.nih.gov/pubmed/25579834.

243. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003; 326(7404):1423–7. http://www.ncbi.nlm.nih.gov/pubmed/12829554.

244. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89–118. http://www.ncbi.nlm.nih.gov/pubmed/15822172.

245. Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2016; 134(21):e468-e495. DOI: 10.1161/CIR.0000000000000456. http://www.ncbi.nlm.nih.gov/pubmed/27754879.

246. Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: A meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4(10):829–39. DOI: 10.1016/S2213-8587(16)30156-5. http://www.ncbi.nlm.nih.gov/pubmed/27477773.

247. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008; 14(2):140–4. DOI: 10.1016/j.cardfail.2007.10.013. http://www.ncbi.nlm.nih.gov/pubmed/18325461.

248. Takano H, Mizuma H, Kuwabara Y, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: The Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77(4):917–25. http://www.ncbi.nlm.nih.gov/pubmed/23502990.

249. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645):1231–9. DOI: 10.1016/S0140-6736(08)61240-4. http://www.ncbi.nlm.nih.gov/pubmed/18757089.

250. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357(22):2248–61. DOI: 10.1056/NEJMoa0706201. http://www.ncbi.nlm.nih.gov/pubmed/17984166.

251. {Smith 2014 #0}.

252. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14):1001–9. http://www.ncbi.nlm.nih.gov/pubmed/8801446.

253. Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016; 316(12):1289–97. DOI: 10.1001/jama.2016.13985. http://www.ncbi.nlm.nih.gov/pubmed/27673306.

254. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360(9326):23–33. http://www.ncbi.nlm.nih.gov/pubmed/12114037.

255. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371(9607):117–25. http://www.ncbi.nlm.nih.gov/pubmed/18191683.

256. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14):1425–35. http://www.ncbi.nlm.nih.gov/pubmed/15755765.

257. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med 2000; 160(4):459–67. http://www.ncbi.nlm.nih.gov/pubmed/10695686.

258. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch. Intern. Med 1998; 158(11):1238–44. http://www.ncbi.nlm.nih.gov/pubmed/9625403.

259. Bucci C, Jackevicius C, McFarlane K, et al. Pharmacist’s contribution in a heart function clinic: Patient perception and medication appropriateness. Can J Cardiol 2003; 19(4):391–6. http://www.ncbi.nlm.nih.gov/pubmed/12704485.

260. Chahine RA, Feldman RL, Giles TD, et al. Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol 1993; 21(6):1365–70. http://www.ncbi.nlm.nih.gov/pubmed/8166777.

261. Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N. Engl. J Med 2008; 358(17):1819–28. http://www.ncbi.nlm.nih.gov/pubmed/18375999.

262. Johnson SM, Mauritson DR, Willerson JT, et al. Verapamil administration in variant angina pectoris. Efficacy shown by ecg monitoring. JAMA 1981; 245(18):1849–51. http://www.ncbi.nlm.nih.gov/pubmed/7230372.

263. National Institute for Health and Care Excellence (NICE), Adams P, Benett I, et al. MI: Secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. Partial update of NICE CG 48.Methods, evidence and recommendations. 2013 (NICE Clinical Guideline; 48) [cited: 2016-04-21]. http://www.nice.org.uk/guidance/cg172/evidence/myocardial-infarction-secondary-prevention-full-guideline-248682925.

264. Catapano AL, Graham I, Backer G de, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272. http://www.ncbi.nlm.nih.gov/pubmed/27567407.

265. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16):1489–99. DOI: 10.1056/NEJMoa1501031. http://www.ncbi.nlm.nih.gov/pubmed/25773378.

266. Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: Potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 2016; 37(17):1373–9. DOI: 10.1093/eurheartj/ehw046. http://www.ncbi.nlm.nih.gov/pubmed/26916794.

267. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25):2387–97. DOI: 10.1056/NEJMoa1410489. http://www.ncbi.nlm.nih.gov/pubmed/26039521.

268. Fei Y, Guyatt GH, Alexander PE, et al. Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. J Eval. Clin Pract. 2017; 24(1):222-231. DOI: 10.1111/jep.12663. http://www.ncbi.nlm.nih.gov/pubmed/28090731.

269. Nussbaumer B, Glechner A, Kaminski-Hartenthaler A, et al. Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int 2016; 113(26):445–53. DOI: 10.3238/arztebl.2016.0445. http://www.ncbi.nlm.nih.gov/pubmed/27412989.

270. Thomopoulos C, Skalis G, Michalopoulou H, et al. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. Clin Cardiol 2015; 38(12):763–9. DOI: 10.1002/clc.22441. http://www.ncbi.nlm.nih.gov/pubmed/26282344.

271. Luo L, Yuan X, Huang W, et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: A meta-analysis. Intern Med J 2015; 45(5):546–57. DOI: 10.1111/imj.12706. http://www.ncbi.nlm.nih.gov/pubmed/25644680.

272. Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: The HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017; 38(29):2264–76. DOI: 10.1093/eurheartj/ehx162. http://www.ncbi.nlm.nih.gov/pubmed/28430910.

273. Liu Z, Hao H, Yin C, et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget 2017; 8(25):41582–9. DOI: 10.18632/oncotarget.15078. http://www.ncbi.nlm.nih.gov/pubmed/28177908.

274. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III - Übersicht über Verordnungs-einschränkungen und –ausschlüsse Nummer 35a – Evolocumab. 2017 [cited: 2018-08-24]. http://www.g-ba.de/downloads/39-261-2932/2017-04-20_AM-RL-III_Evolocumab_BAnz.pdf.

275. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht über Verordnungseinschränkungen und -ausschlüsse Evolocumab. 2016 [cited: 2018-08-24]. http://www.g-ba.de/downloads/39-261-2600/2016-06-02_AM-RL-III_Evolocumab_BAnz.pdf.

276. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht über Verordnungseinschränkungen und -ausschlüsse Alirocumab. 2016 [cited: 2018-08-24]. http://www.g-ba.de/downloads/39-261-2676/2016-08-04_AM-RL-III_Alirocumab_BAnz.pdf.

277. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379(22):2097-2107. DOI: 10.1056/NEJMoa1801174. http://www.ncbi.nlm.nih.gov/pubmed/30403574.

278. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18):1713–22. DOI: 10.1056/NEJMoa1615664. http://www.ncbi.nlm.nih.gov/pubmed/28304224.

279. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163(1):40–51. DOI: 10.7326/M14-2957. http://www.ncbi.nlm.nih.gov/pubmed/25915661.

280. Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. Eur Heart J 2016; 37(6):536–45. DOI: 10.1093/eurheartj/ehv563. http://www.ncbi.nlm.nih.gov/pubmed/26578202.

281. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: A meta-analysis of 25 randomized, controlled trials. BMC Med 2015; 13:123. DOI: 10.1186/s12916-015-0358-8. http://www.ncbi.nlm.nih.gov/pubmed/26099511.

282. Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017; 4:CD011748. DOI: 10.1002/14651858.CD011748.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28453187.

283. Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial. Eur Heart J 2016; 37(48):3588–95. DOI: 10.1093/eurheartj/ehw388. http://www.ncbi.nlm.nih.gov/pubmed/27572070.

284. Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med 2017; 377(7):633–43. DOI: 10.1056/NEJMoa1701131. http://www.ncbi.nlm.nih.gov/pubmed/28813214.

285. Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017; 2(10):1069–78. DOI: 10.1001/jamacardio.2017.2762. http://www.ncbi.nlm.nih.gov/pubmed/28832867.

286. Arrieta A, Hong JC, Khera R, et al. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol 2017; 2(12):1369–74. DOI: 10.1001/jamacardio.2017.3655. http://www.ncbi.nlm.nih.gov/pubmed/29049467.

287. Kazi DS, Penko J, Coxson PG, et al. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA 2017; 318(8):748–50. DOI: 10.1001/jama.2017.9924. http://www.ncbi.nlm.nih.gov/pubmed/28829863.

288. Mark DB, Schulman KA. PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA 2017; 318(8):711–2. DOI: 10.1001/jama.2017.8907. http://www.ncbi.nlm.nih.gov/pubmed/28829851.

289. Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93(10):1826–35. http://www.ncbi.nlm.nih.gov/pubmed/8635262.

290. Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: A randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345(8953):811–6. http://www.ncbi.nlm.nih.gov/pubmed/7898227.

291. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 2013; 128(24):2567–76. DOI: 10.1161/CIRCULATIONAHA.113.002432. http://www.ncbi.nlm.nih.gov/pubmed/24056686.

292. National Institute for Health and Care Excellence (NICE). Appendix A: Summary of new evidence from 4-year surveillance of Myocardial infarction. 2016 (NICE Guideline; 172) [cited: 2018-06-13]. http://www.nice.org.uk/guidance/cg172/evidence/appendix-a-summary-of-new-evidence-pdf-4479686174.

293. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: A meta-analysis of randomized trials. Am J Med 2014; 127(10):939–53. DOI: 10.1016/j.amjmed.2014.05.032. http://www.ncbi.nlm.nih.gov/pubmed/24927909.

294. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis. Am. J. Cardiol. 2002; 89(2A):18A-25A. http://www.ncbi.nlm.nih.gov/pubmed/11835907.

295. Dahal K, Hendrani A, Sharma SP, et al. Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis. JAMA Intern Med 2018; 178(7):913-920. DOI: 10.1001/jamainternmed.2018.0850. http://www.ncbi.nlm.nih.gov/pubmed/29799995.

296. Montalescot G, Collet JP, Ecollan P, et al. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: The ACCOAST-PCI study. J Am Coll Cardiol 2014; 64(24):2563–71. DOI: 10.1016/j.jacc.2014.08.053. http://www.ncbi.nlm.nih.gov/pubmed/25524333.

297. Uzunhasan I, Yildiz A, Coskun U, et al. Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction. Scand J Clin Lab Invest 2009; 69(5):545–9. DOI: 10.1080/00365510902802278. http://www.ncbi.nlm.nih.gov/pubmed/19347740.

298. Di Pasquale P, Alessi V, Barberi O, et al. The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: Safety and tolerability study. Int J Cardiol 2001; 77(2-3):119-27; discussion 128-9. http://www.ncbi.nlm.nih.gov/pubmed/11182173.

299. Beygui F, Cayla G, Roule V, et al. Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. J Am Coll Cardiol 2016; 67(16):1917–27. DOI: 10.1016/j.jacc.2016.02.033. http://www.ncbi.nlm.nih.gov/pubmed/27102506.

300. Wu C-T, Wang Z-H, Li Z-Q, et al. Effect of spironolactone on cardiac remodeling after acute myocardial infarction. World J Emerg Med 2013; 4(1):48–53. DOI: 10.5847/wjem.j.1920-8642.2013.01.009. http://www.ncbi.nlm.nih.gov/pubmed/25215092.

301. Di Pasquale P, Cannizzaro S, Scalzo S, et al. Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. Am Heart J 2005; 150(5):919. DOI: 10.1016/j.ahj.2005.03.032. http://www.ncbi.nlm.nih.gov/pubmed/16290961.

302. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107(20):2559–65. DOI: 10.1161/01.CIR.0000068340.96506.0F. http://www.ncbi.nlm.nih.gov/pubmed/12732605.

303. Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001; 141(1):41–6. DOI: 10.1067/mhj.2001.111258. http://www.ncbi.nlm.nih.gov/pubmed/11136485.

304. Servier Deutschland GmbH, Gelbe Liste Online. Procoralan® 5 mg, Filmtbl. Fachinformation. 2018 [cited: 2018-06-08]. http://www.gelbe-liste.de/produkte/Procoralan-5-mg-Filmtbl_481159/fachinformation.

305. Berlin-Chemie AG, Gelbe Liste Online. Ranexa® 375 mg Retardtabletten. Fachinformation. 2016 [cited: 2018-06-08]. http://www.gelbe-liste.de/produkte/Ranexa-375-mg-Retardtabletten_511772/fachinformation.

306. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290(21):2805–16. http://www.ncbi.nlm.nih.gov/pubmed/14657064.

307. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281(20):1927–36. http://www.ncbi.nlm.nih.gov/pubmed/10349897.

308. Elkayam U. Tolerance to organic nitrates: Evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991; 114(8):667–77. http://www.ncbi.nlm.nih.gov/pubmed/2003715.

309. Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, et al. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev 2017; 2:CD011747. DOI: 10.1002/14651858.CD011747.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28178363.

310. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009(3):CD001841. http://www.ncbi.nlm.nih.gov/pubmed/19588327.

311. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371(12):1091–9. DOI: 10.1056/NEJMoa1406430. http://www.ncbi.nlm.nih.gov/pubmed/25176136.

312. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345(8951):669–85. http://www.ncbi.nlm.nih.gov/pubmed/7661937.

313. Gruppo Italiano per lo Studio della Sopravvivenza nell‘infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906):1115–22. http://www.ncbi.nlm.nih.gov/pubmed/7910229.

314. Ständige Impfkommission am Robert Koch Institut (STIKO). Mitteilung der Ständigen Impfkommission am Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut - 2017/2018. Epidemiol Bull RKI 2017(34):333–80. DOI: 10.17886/EpiBull-2017-044.

315. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018; 378(4):345–53. DOI: 10.1056/NEJMoa1702090. http://www.ncbi.nlm.nih.gov/pubmed/29365305.

316. Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: A systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012; 5(4):476–90. DOI: 10.1161/CIRCINTERVENTIONS.112.970954. http://www.ncbi.nlm.nih.gov/pubmed/22872053.

317. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: Meta-analysis of randomized controlled trials. Arch. Intern. Med 2012; 172(4):312–9. DOI: 10.1001/archinternmed.2011.1484. http://www.ncbi.nlm.nih.gov/pubmed/22371919.

318. Thomas S, Gokhale R, Boden WE, et al. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013; 29(4):472–82. DOI: 10.1016/j.cjca.2012.07.010. http://www.ncbi.nlm.nih.gov/pubmed/23010084.

319. Gorenoi V, Schonermark MP, Hagen A. Perkutane Koronarinterventionen zusätzlich zur optimalen medikamentösen Therapie bei stabiler Angina Pectoris. 2011 (Schriftenreihe Health Technology Assessment; 115) [cited: 2018-11-22].

320. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia: A Collaborative Meta-analysis of Contemporary Randomized Clinical Trials. JAMA Intern Med 2014; 174(2):232–40. DOI: 10.1001/jamainternmed.2013.12855. http://www.ncbi.nlm.nih.gov/pubmed/24296791.

321. Bangalore S, Pursnani S, Kumar S, et al. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation 2013; 127(7):769–81. DOI: 10.1161/CIRCULATIONAHA.112.131961. http://www.ncbi.nlm.nih.gov/pubmed/23325526.

322. Jeremias A, Kaul S, Rosengart TK, et al. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009; 122(2):152–61. http://www.ncbi.nlm.nih.gov/pubmed/19185092.

323. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344(8922):563–70. http://www.ncbi.nlm.nih.gov/pubmed/7914958.

324. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010; 122(10):949–57. http://www.ncbi.nlm.nih.gov/pubmed/20733102.

325. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364(17):1607–16. http://www.ncbi.nlm.nih.gov/pubmed/21463150.

326. Boden WE, O‘Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356(15):1503–16. http://www.ncbi.nlm.nih.gov/pubmed/17387127.

327. Wijeysundera HC, Nallamothu BK, Krumholz HM, et al. Meta-analysis: Effects of percutaneous coronary intervention versus medical therapy on angina relief. Ann Intern Med 2010; 152(6):370–9. DOI: 10.7326/0003-4819-152-6-201003160-00007. http://www.ncbi.nlm.nih.gov/pubmed/20231568.

328. Sipahi I, Akay MH, Dagdelen S, et al. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: Meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med 2014; 174(2):223–30. DOI: 10.1001/jamainternmed.2013.12844. http://www.ncbi.nlm.nih.gov/pubmed/24296767.

329. Li Q, Zhang Z, Yin RX. Drug-eluting stents or coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of four randomized trials and seventeen observational studies. Trials 2013; 14:133. DOI: 10.1186/1745-6215-14-133. http://www.ncbi.nlm.nih.gov/pubmed/23782856.

330. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31(20):2501–55. http://www.ncbi.nlm.nih.gov/pubmed/20802248.

331. Head SJ, Kaul S, Mack MJ, et al. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. Eur Heart J 2013; 34(32):2510–8. DOI: 10.1093/eurheartj/eht059. http://www.ncbi.nlm.nih.gov/pubmed/23425523.

332. Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC. Cardiovasc Interv. 2008; 1(5):483–91. http://www.ncbi.nlm.nih.gov/pubmed/19463349.

333. Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007; 334(7594):617. http://www.ncbi.nlm.nih.gov/pubmed/17337458.

334. Blazek S, Holzhey D, Jungert C, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC. Cardiovasc Interv. 2013; 6(1):20–6. DOI: 10.1016/j.jcin.2012.09.008. http://www.ncbi.nlm.nih.gov/pubmed/23347858.

335. Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009; 53(25):2324–31. DOI: 10.1016/j.jacc.2009.03.032. http://www.ncbi.nlm.nih.gov/pubmed/19539141.

336. Deb S, Wijeysundera HC, Ko DT, et al. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: A systematic review. JAMA 2013; 310(19):2086–95. DOI: 10.1001/jama.2013.281718. http://www.ncbi.nlm.nih.gov/pubmed/24240936.

337. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381(9867):629–38. DOI: 10.1016/S0140-6736(13)60141-5. http://www.ncbi.nlm.nih.gov/pubmed/23439102.

338. Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: Six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008; 118(4):381–8. http://www.ncbi.nlm.nih.gov/pubmed/18606919.

339. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360(10):961–72. http://www.ncbi.nlm.nih.gov/pubmed/19228612.

340. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012; 366(16):1467–76. DOI: 10.1056/NEJMoa1110717. http://www.ncbi.nlm.nih.gov/pubmed/22452338.

341. Fortuna D, Nicolini F, Guastaroba P, et al. Coronary artery bypass grafting vs percutaneous coronary intervention in a ‚real-world‘ setting: A comparative effectiveness study based on propensity score-matched cohorts. Eur J Cardiothorac Surg 2013; 44(1):e16-e24. DOI: 10.1093/ejcts/ezt197. http://www.ncbi.nlm.nih.gov/pubmed/23628951.

342. Takagi H, Yamamoto H, Iwata K, et al. Drug-eluting stents increase late mortality compared with coronary artery bypass grafting in triple-vessel disease: A meta-analysis of randomized controlled and risk-adjusted observational studies. Int J Cardiol 2012; 159(3):230–3. DOI: 10.1016/j.ijcard.2012.05.046. http://www.ncbi.nlm.nih.gov/pubmed/22664367.

343. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes - Langfassung, 1. Auflage. Version 4. 2014 [cited: 2017-01-12]. DOI: 10.6101/AZQ/000213. http://doi.org/10.6101/AZQ/000213.

344. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360(24):2503–15. http://www.ncbi.nlm.nih.gov/pubmed/19502645.

345. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010; 55(5):432–40. http://www.ncbi.nlm.nih.gov/pubmed/20117456.

346. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for Multivessel Revascularization in Patients with Diabetes. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585. http://www.ncbi.nlm.nih.gov/pubmed/23121323.

347. Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013; 43(5):1006–13. DOI: 10.1093/ejcts/ezt017. http://www.ncbi.nlm.nih.gov/pubmed/23413014.

348. Hakeem A, Garg N, Bhatti S, et al. Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta-analysis of Randomized Clinical Data. J Am Heart Assoc 2013; 2(4):e000354. DOI: 10.1161/JAHA.113.000354. http://www.ncbi.nlm.nih.gov/pubmed/23926119.

349. Li X, Kong M, Jiang D, et al. Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: A meta-analysis. Interact Cardiovasc Thorac Surg 2014; 18(3):347–54. DOI: 10.1093/icvts/ivt509. http://www.ncbi.nlm.nih.gov/pubmed/24345688.

350. Taylor HA, Deumite NJ, Chaitman BR, et al. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. Circulation 1989; 79(6):1171–9. http://www.ncbi.nlm.nih.gov/pubmed/2785870.

351. Park DW, Kim YH, Yun SC, et al. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol 2010; 56(17):1366–75. http://www.ncbi.nlm.nih.gov/pubmed/20946993.

352. Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009; 53(19):1760–8. DOI: 10.1016/j.jacc.2009.01.035. http://www.ncbi.nlm.nih.gov/pubmed/19422982.

353. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364(18):1718–27. http://www.ncbi.nlm.nih.gov/pubmed/21463149.

354. Taggart DP, Kaul S, Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol 2008; 51(9):885–92. DOI: 10.1016/j.jacc.2007.09.067. http://www.ncbi.nlm.nih.gov/pubmed/18308155.

355. Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 2011; 57(5):538–45. http://www.ncbi.nlm.nih.gov/pubmed/21272743.

356. Morice MC, Serruys PW, Kappetein AP, et al. Five-Year Outcomes in Patients with Left Main Disease Treated with Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the SYNTAX Trial. Circulation 2014; 129(23):2388–94. DOI: 10.1161/CIRCULATIONAHA.113.006689. http://www.ncbi.nlm.nih.gov/pubmed/24700706.

357. Stone GW, Serruys PW, Sabik J, et al. Evaluation of XIENCE PRIMET Everolimus Eluting Stent System (EECSS) or XIENCE V® EECSS or XIENCE XpeditionT EECSS or XIENCE PRO EECSS Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization. 2013 [cited: 2014-03-18]. http://www.clinicaltrials.gov/ct2/show/study/NCT01205776.

358. Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 2008; 51(5):538–45. http://www.ncbi.nlm.nih.gov/pubmed/18237682.

359. Capodanno D, Stone GW, Morice MC, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: A meta-analysis of randomized clinical data. J Am Coll Cardiol 2011; 58(14):1426–32. DOI: 10.1016/j.jacc.2011.07.005. http://www.ncbi.nlm.nih.gov/pubmed/21939824.

360. Desch S, Boudriot E, Rastan A, et al. Bypass surgery versus percutaneous coronary intervention for the treatment of unprotected left main disease. A meta-analysis of randomized controlled trials. Herz 2013; 38(1):48–56. DOI: 10.1007/s00059-012-3596-y. http://www.ncbi.nlm.nih.gov/pubmed/22407425.

361. Alam M, Huang HD, Shahzad SA, et al. Percutaneous coronary intervention vs. coronary artery bypass graft surgery for unprotected left main coronary artery disease in the drug-eluting stents era—an aggregate data meta-analysis of 11,148 patients. Circ J 2013; 77(2):372–82. http://www.ncbi.nlm.nih.gov/pubmed/23123552.

362. Sa MP, Soares AM, Lustosa PC, et al. Meta-analysis of 5674 patients treated with percutaneous coronary intervention and drug-eluting stents or coronary artery bypass graft surgery for unprotected left main coronary artery stenosis. Eur J Cardiothorac Surg 2013; 43(1):73–80. DOI: 10.1093/ejcts/ezs204. http://www.ncbi.nlm.nih.gov/pubmed/22518037.

363. Cao C, Manganas C, Bannon P, et al. Drug-eluting stents versus coronary artery bypass graft surgery in left main coronary artery disease: A meta-analysis of early outcomes from randomized and nonrandomized studies. J Thorac Cardiovasc Surg 2013; 145(3):738–47. DOI: 10.1016/j.jtcvs.2012.02.004. http://www.ncbi.nlm.nih.gov/pubmed/22405674.

364. Farooq V, van KD, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: Development and validation of SYNTAX score II. Lancet 2013; 381(9867):639–50. DOI: 10.1016/S0140-6736(13)60108-7. http://www.ncbi.nlm.nih.gov/pubmed/23439103.

365. World Health Organization (WHO). Rehabilitation after cardiovascular diseases, with special emphasis on developing countries. Report of a WHO Expert Committee. WHO Tech Rep Ser 1993; 831:1–122. http://www.ncbi.nlm.nih.gov/pubmed/8351937.

366. Bein T, Bischoff M, Brückner U, et al. Lagerungstherapie und Frühmobilisation zur Prophylaxe oder Therapie von pulmonalen Funktionsstörungen. S2e-Leitlinie. 2015 [cited: 2018-04-20]. http://www.awmf.org/uploads/tx_szleitlinien/001-015l_S2e_Lagerungstherapie_Fr%C3%BChmobilisation_pulmonale_Funktionsst%C3%B6rungen_2015-05.pdf.

367. Iliou M-C, Pavy B, Martinez J, et al. Exercise training is safe after coronary stenting: A prospective multicentre study. Eur J Prev Cardiol 2015; 22(1):27–34. DOI: 10.1177/2047487313505819. http://www.ncbi.nlm.nih.gov/pubmed/24057686.

368. Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016; 23(18):1914–39. DOI: 10.1177/2047487316671181. http://www.ncbi.nlm.nih.gov/pubmed/27777324.

369. van Halewijn G, Deckers J, Tay HY, et al. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol 2017; 232:294–303. DOI: 10.1016/j.ijcard.2016.12.125. http://www.ncbi.nlm.nih.gov/pubmed/28094128.

370. Minneboo M, Lachman S, Snaterse M, et al. Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease: The RESPONSE-2 Trial. J Am Coll Cardiol 2017; 70(3):318–27. DOI: 10.1016/j.jacc.2017.05.041. http://www.ncbi.nlm.nih.gov/pubmed/28705312.

371. Powell R, McGregor G, Ennis S, et al. Is exercise-based cardiac rehabilitation effective? A systematic review and meta-analysis to re-examine the evidence. BMJ open 2018; 8(3):e019656. DOI: 10.1136/bmjopen-2017-019656. http://www.ncbi.nlm.nih.gov/pubmed/29540415.

372. Campbell NC, Thain J, Deans HG, et al. Secondary prevention clinics for coronary heart disease: Randomised trial of effect on health. Br Med J 1998; 316(7142):1434–7. http://www.ncbi.nlm.nih.gov/pubmed/9572758.

373. Cupples ME, McKnight A. Randomised controlled trial of health promotion in general practice for patients at high cardiovascular risk. Br Med J 1994; 309(6960):993–6. http://www.ncbi.nlm.nih.gov/pubmed/7950723.

 

zuletzt verändert: 10.04.2019 17:28